β‑catenin knockdown enhances the effects of fluorouracil in the breast cancer cell line MDA‑MB‑468

Lv,Xinquan; Pang,Xia; Jin,Xiangdong; Song,Yimin; Li,Huixiang

doi:10.3892/br.2014.353

β‑catenin knockdown enhances the effects of fluorouracil in the breast cancer cell line MDA‑MB‑468

Authors:
- Xinquan Lv
- Xia Pang
- Xiangdong Jin
- Yimin Song
- Huixiang Li
View Affiliations

Affiliations: Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: August 26, 2014 https://doi.org/10.3892/br.2014.353
Pages: 910-914

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor proliferation, drug resistance and cell stemness are major difficulties that are encountered during breast cancer therapy and are often responsible for disease progression and cancer‑related mortality. β‑catenin is considered to be an invasion gene in breast cancer. However, how β‑catenin regulates breast cancer cell proliferation and stemness remains unclear. In the present study, β‑catenin knockdown by small interfering RNA in MDA‑MB‑468, a highly metastatic breast cancer cell line, inhibited the expression of β‑catenin, Oct3/4 (stemness), survivin (anti‑apoptosis) and BCRP (drug resistance). Knockdown of β‑catenin enhanced the effects of fluorouracil (5‑FU) chemotherapy on the proliferation of MDA‑MB‑468 cells. Thus, these preliminary results indicate that β‑catenin knockdown enhanced 5‑FU‑induced proliferation inhibition in the breast cancer cell line MDA‑MB‑468, and indicate that combining 5‑FU with gene silencing could be an advantageous option for enhancing the curative effect of chemotherapy in breast cancer and other malignancies.

View Figures

View References

1	Eramo A, Ricci-Vitiani L, Zeuner A, et al: Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 13:1238–1241. 2006. View Article : Google Scholar : PubMed/NCBI
2	Dean M: ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia. 14:3–9. 2009. View Article : Google Scholar : PubMed/NCBI
3	Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005. View Article : Google Scholar
4	Phillips TM, McBride WH and Pajonk F: The response of CD24(−/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 98:1777–1785. 2006.
5	Tanei T, Morimoto K, Shimazu K, et al: Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 15:4234–4241. 2009. View Article : Google Scholar : PubMed/NCBI
6	Reya T and Clevers H: Wnt signalling in stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
7	Li Y, Welm B, Podsypanina K, et al: Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci USA. 100:15853–15858. 2003. View Article : Google Scholar : PubMed/NCBI
8	Liu BY, McDermott SP, Khwaja SS and Alexander CM: The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc Natl Acad Sci USA. 101:4158–4163. 2004. View Article : Google Scholar : PubMed/NCBI
9	Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem. 193:265–275. 1951.PubMed/NCBI
10	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
11	Steeg PS: Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 12:895–904. 2006. View Article : Google Scholar : PubMed/NCBI
12	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
13	Fu Y, Zheng S, An N, et al: β-catenin as a potential key target for tumor suppression. Int J Cancer. 129:1541–1551. 2011.
14	DiMeo TA, Anderson K, Phadke P, et al: A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 69:5364–5373. 2009. View Article : Google Scholar : PubMed/NCBI
15	Lin SY, Xia W, Wang JC, et al: Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA. 97:4262–4266. 2000. View Article : Google Scholar : PubMed/NCBI
16	Brabletz T, Jung A, Reu S, et al: Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci USA. 98:10356–10361. 2001. View Article : Google Scholar : PubMed/NCBI
17	Khan S, Aspe JR, Asumen MG, et al: Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br J Cancer. 100:1073–1086. 2009. View Article : Google Scholar : PubMed/NCBI
18	Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA and Rosen JM: WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA. 104:618–623. 2007. View Article : Google Scholar : PubMed/NCBI
19	Schöler HR, Dressler GR, Balling R, Rohdewohld H and Gruss P: Oct-4: a germline-specific transcription factor mapping to the mouse t-complex. EMBO J. 9:2185–2195. 1990.PubMed/NCBI
20	Schöler HR, Ruppert S, Suzuki N, Chowdhury K and Gruss P: New type of POU domain in germ line-specific protein Oct-4. Nature. 344:435–439. 1990.PubMed/NCBI
21	Nakanishi T, Chumsri S, Khakpour N, et al: Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer. 102:815–826. 2010. View Article : Google Scholar : PubMed/NCBI
22	Nguyen NP, Almeida FS, Chi A, et al: Molecular biology of breast cancer stem cells: potential clinical applications. Cancer Treat Rev. 36:485–491. 2010. View Article : Google Scholar : PubMed/NCBI
23	Abaan OD, Mutlu PK, Baran Y, Atalay C and Gunduz U: Multidrug resistance mediated by MRP1 gene overexpression in breast cancer patients. Cancer Invest. 27:201–205. 2009. View Article : Google Scholar : PubMed/NCBI
24	Wang JS, Zheng CL, Wang YJ, et al: Gene silencing of beta-catenin by RNAi inhibits cell proliferation in human esophageal cancer cells in vitro and in nude mice. Dis Esophagus. 22:151–162. 2009. View Article : Google Scholar : PubMed/NCBI